Browsing Tag
Mesoblast
4 posts
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
Cats finally get a disease-modifying therapy candidate as Gallant pilot data clears the bar and FDA opens the fast lane
Gallant reports positive randomised trial data for feline osteoarthritis stem cell therapy and wins FDA expanded conditional approval eligibility. Read the full analysis.
Polynovo stock falls as diabetes wound trial results spotlight NovoSorb promise
Polynovo (ASX: PNV) shares slipped 1.37% as NovoSorb diabetes wound trial results showed faster healing in large wounds. Can reimbursement shifts revive growth?
FDA grants orphan drug exclusivity to Mesoblast’s Ryoncil for pediatric SR-aGvHD
Find out how Mesoblast's FDA approval for Ryoncil in pediatric SR-aGvHD sets a new benchmark in stem cell therapy and market exclusivity strategy.